Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with <i>MET</i>ex14 skipping.
Xiuning Le(The University of Texas MD Anderson Cancer Center), Paul K. Paik(Memorial Sloan Kettering Cancer Center), PierFranco Conte(University of Padua), Santiago Viteri(Instituto Oncológico Dr. Rosell), Hiroshi Sakai(Hiroshima University), John V. Heymach(The University of Texas MD Anderson Cancer Center), Hélène Senellart(Institut Génétique Nantes Atlantique), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), Julien Mazières(Université Toulouse III - Paul Sabatier), Rolf Bruns(Inserm), Byoung Chul Cho(Yonsei University), Rémi Veillon(Centre Hospitalier Universitaire de Bordeaux), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Jan P. van Meerbeeck(Antwerp University Hospital), Enriqueta Felip(Institut Català d'Ornitologia), Marina Chiara Garassino(University of Chicago), J. Scheele(Center for Global Development), Josef Straub(Inserm), Alexis B. Cortot(Centre National de la Recherche Scientifique)
Cited by 4
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k